Securities code: 300942 securities abbreviation: Shenzhen Bioeasy Biotechnology Co.Ltd(300942) Announcement No.: 2022-010 Shenzhen Bioeasy Biotechnology Co.Ltd(300942)
Announcement of resolutions of the 10th meeting of the second board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of directors
Shenzhen Bioeasy Biotechnology Co.Ltd(300942) (hereinafter referred to as “the company”) held the 10th meeting of the second board of directors on February 25, 2022 (Friday) in the company’s conference room on the 5th floor, No. 2-1 Liuxian 1st Road, Bao’an District, Shenzhen by combining on-site and communication voting. The notice of this meeting was sent to all directors by email and communication on February 21, 2022.
The meeting was convened and presided over by Mr. Zhu Hai, chairman of the board of directors. There were 9 directors who should attend the meeting and 9 directors who actually attended the meeting (3 directors who attended the meeting on site and 6 directors who attended by communication); All supervisors and senior managers of the company attended the meeting as nonvoting delegates. The convening, notification, convening and voting procedures of this meeting comply with the relevant provisions of the company law and other relevant laws, administrative regulations, normative documents, departmental rules and the articles of association. The meeting is legal and effective.
2、 Deliberations of the board meeting
After deliberation by the directors present at the meeting and voting by open ballot in writing, the deliberation results are as follows:
(I) deliberated and passed the proposal on cooperative investment with professional investment institutions
In order to make better use of the strength and resource advantages of professional investment institutions to carry out the industrial layout related to the company’s business and improve the company’s comprehensive competitiveness, it is agreed that the company and professional investment institutions Shenzhen Ruihai private equity investment fund management Co., Ltd. and natural person Zhou Jinquan Lu Ye cooperates to establish Shenzhen Zhengrui investment partnership (limited partnership) (tentative name, subject to industrial and commercial approval, hereinafter referred to as the “partnership”), and the initial scale of the partnership is RMB 100 million. As a limited partner, the company subscribed capital contribution of 89 million yuan, accounting for 89%, and the capital contribution method is its own capital in currency.
Voting result: 9 affirmative votes; No negative vote; There were no abstentions.
The independent directors expressed their independent opinions on the matter, and the announcement on cooperative investment with professional investment institutions (Announcement No.: 2022-012) was published on the information disclosure website http://www.cn.info.com.cn.
The motion was passed.
(II) the proposal on the use of some temporarily idle raised funds for cash management was deliberated and adopted. In view of the need for a certain period for the implementation and construction of raised investment projects, in order to improve the efficiency of fund use, it was agreed that the company would not affect the normal construction of raised investment projects and the safety of raised funds, Use part of the temporarily idle raised funds with a total amount of no more than RMB 100 million for cash management, and invest in principal guaranteed products with high safety and good liquidity for no more than 12 months. The service life is valid within 12 months from the date of deliberation and approval by the board of directors, and can be recycled and used within the above-mentioned amount and period, It is agreed to authorize the general manager of the company to make specific decisions on the investment within the above validity period and limit, and sign relevant documents, which shall be implemented by the financial department. Voting result: 9 affirmative votes; No negative vote; There were no abstentions.
The independent directors gave their independent opinions on the matter, and the continuous supervision organization issued verification opinions. The announcement on the use of some temporarily idle raised funds for cash management (Announcement No.: 2022-013) was published on the information disclosure website cninfo (www.cn. Info. Com. CN) on the same day.
The motion was passed.
3、 Documents for future reference
1. Resolutions of the 10th meeting of the second board of directors of the company;
2. Independent opinions of independent directors on matters related to the 10th meeting of the second board of directors.
It is hereby announced.
Shenzhen Bioeasy Biotechnology Co.Ltd(300942) board of directors February 26, 2022
